Analyst Research Report Snapshot

Title:

GLAXOSMITHKLINE - BEYOND THE CLIFF

Price:

$10.00

Provider:

Edison Investment Research

Date:

08 Feb 2010

Pages:

2

Type:

AcrobatPDF

Companies referenced:

GSK.L

Available for Immediate Download
Summary:

GlaxoSmithKline’s transformation under CEO Andrew Witty continues, with clear evidence of the changes, especially in emerging markets. In addition, it is now targeting an extra £500m in cost savings. The company is largely through its patent cliff, and with 20 products launched in the last three years it should enter a sustained revenue growth phase. The shares trade at a discount to global peers (FY10 P/E of 10.6 vs 11.0) and are supported by a yield of 5.3%.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.